COMBIVENT RESPIMAT

Albuterol/Ipratropium

COMBIVENT RESPIMAT

SABASAMA SMI

Ipratropium bromide / Albuterol sulfate · Boehringer Ingelheim

Clinical Reference

Active Medication & Mechanism

Ipratropium bromide SAMA
20 mcg per actuation

Short-acting muscarinic antagonist (anticholinergic). Blocks vagal cholinergic tone at M3 receptors, reducing bronchospasm in COPD.
Albuterol sulfate SABA
100 mcg per actuation (albuterol base)

Short-acting beta2-adrenergic agonist. Relaxes bronchial smooth muscle by stimulating beta2-receptors, providing rapid bronchodilation.

FDA-Approved Dosing by Indication

// approval varies by strength + age

COPD

1/1 approved regimens

Strength	Population	Dose & Frequency	Total Daily	Status
20/100 mcg	Adults (≥18 years)	1 inhalation four times a day (maximum 6 inhalations in 24 hours) Treatment of bronchospasm associated with COPD in patients requiring more than one bronchodilator.	80/400 mcg (standard); max 120/600 mcg	FDA Approved

20/100 mcg FDA Approved

Pop · Adults (≥18 years)

1 inhalation four times a day (maximum 6 inhalations in 24 hours)

Treatment of bronchospasm associated with COPD in patients requiring more than one bronchodilator.

Total · 80/400 mcg (standard); max 120/600 mcg

Asthma

0/1 approved regimens

Strength	Population	Dose & Frequency	Total Daily	Status
Any strength	All patients	—	—	Not Approved Combivent Respimat is not indicated for asthma.

Any strength Not Approved

Pop · All patients

—

Total · — Combivent Respimat is not indicated for asthma.

Acute Use

1/1 approved regimens

Strength	Population	Dose & Frequency	Total Daily	Status
20/100 mcg	Adults with COPD	1 inhalation as needed; maximum 6 inhalations/24h The SABA+SAMA combination provides bronchodilation for acute COPD symptoms.	Maximum 120/600 mcg	FDA Approved

20/100 mcg FDA Approved

Pop · Adults with COPD

1 inhalation as needed; maximum 6 inhalations/24h

The SABA+SAMA combination provides bronchodilation for acute COPD symptoms.

Total · Maximum 120/600 mcg